Clinical Trial Update: A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201) [Phase 1]

View source ↗

Summary

Fortitude-201 (bemarituzumab) is a Phase 1 trial evaluating bemarituzumab alone or in combination with other anti-cancer therapies in FGFR2b-overexpressing squa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Lung

Drugs mentioned

• Bemarituzumab (bemarituzumab)

Snippet

Sponsor: Amgen | Conditions: Squamous-Cell Non-Small-Cell Lung Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-03-25